Related Experiment Video

Updated: Jun 6, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer

F Di Fiore1, R Sesboüé, P Michel

  • 1Faculty of Medicine, Institute for Biomedical Research, 22 Boulevard Gambetta, 76183 Rouen, France. frederic.di-fiore@chu-rouen.fr

British Journal of Cancer
|December 9, 2010
PubMed

Insights

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) improve outcomes for metastatic colorectal cancer (MCRC). KRAS mutation testing is essential for guiding anti-EGFR therapy and predicting patient response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacogenomics

Background:

  • Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) have significantly improved outcomes for patients with metastatic colorectal cancer (MCRC).
  • Despite improved efficacy, significant variability in patient response to anti-EGFR mAbs necessitates the identification of predictive biomarkers.
  • Current treatment guidelines restrict anti-EGFR mAb use to patients without KRAS mutations.

Purpose of the Study:

  • To review the established and emerging clinical and molecular markers that predict response or resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer.
  • To highlight the importance of KRAS genotyping as a mandatory predictive marker in routine practice.

Main Methods:

  • Review of clinical studies and molecular analyses investigating biomarkers for anti-EGFR therapy in MCRC.
  • Analysis of somatic mutations (KRAS, BRAF, PIK3CA), gene amplifications (EGFR), protein expression (EGFR ligands, PTEN), and TP53 status.
  • Consideration of germline polymorphisms within the EGFR pathway and immunoglobulin receptors.

Main Results:

  • Somatic KRAS mutations are a validated marker of resistance to anti-EGFR mAbs.
  • EGFR amplification, EGFR ligand overexpression, and TP53 inactivation are associated with sensitivity.
  • BRAF mutations, PIK3CA mutations, and PTEN loss are associated with resistance.
  • Germline polymorphisms may also influence response but require further validation.

Conclusions:

  • KRAS genotyping is currently the only mandatory validated marker for guiding anti-EGFR mAb therapy in MCRC.
  • Further validation of other molecular markers, including gene amplifications, mutations, and germline polymorphisms, is needed to optimize targeted therapy selection.
  • Personalized treatment strategies incorporating comprehensive biomarker analysis are crucial for maximizing efficacy and minimizing resistance in MCRC patients receiving anti-EGFR therapies.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...